Literature DB >> 24380842

Lyssavirus infection: 'low dose, multiple exposure' in the mouse model.

Ashley C Banyard1, Derek M Healy2, Sharon M Brookes2, Katja Voller2, Daniel J Hicks3, Alejandro Núñez3, Anthony R Fooks4.   

Abstract

The European bat lyssaviruses (EBLV-1 and EBLV-2) are zoonotic pathogens present within bat populations across Europe. The maintenance and transmission of lyssaviruses within bat colonies is poorly understood. Cases of repeated isolation of lyssaviruses from bat roosts have raised questions regarding the maintenance and intraspecies transmissibility of these viruses within colonies. Furthermore, the significance of seropositive bats in colonies remains unclear. Due to the protected nature of European bat species, and hence restrictions to working with the natural host for lyssaviruses, this study analysed the outcome following repeat inoculation of low doses of lyssaviruses in a murine model. A standardized dose of virus, EBLV-1, EBLV-2 or a 'street strain' of rabies (RABV), was administered via a peripheral route to attempt to mimic what is hypothesized as natural infection. Each mouse (n=10/virus/group/dilution) received four inoculations, two doses in each footpad over a period of four months, alternating footpad with each inoculation. Mice were tail bled between inoculations to evaluate antibody responses to infection. Mice succumbed to infection after each inoculation with 26.6% of mice developing clinical disease following the initial exposure across all dilutions (RABV, 32.5% (n=13/40); EBLV-1, 35% (n=13/40); EBLV-2, 12.5% (n=5/40)). Interestingly, the lowest dose caused clinical disease in some mice upon first exposure ((RABV, 20% (n=2/10) after first inoculation; RABV, 12.5% (n=1/8) after second inoculation; EBLV-2, 10% (n=1/10) after primary inoculation). Furthermore, five mice developed clinical disease following the second exposure to live virus (RABV, n=1; EBLV-1, n=1; EBLV-2, n=3) although histopathological examination indicated that the primary inoculation was the most probably cause of death due to levels of inflammation and virus antigen distribution observed. All the remaining mice (RABV, n=26; EBLV-1, n=26; EBLV-2, n=29) survived the tertiary and quaternary inoculations although the serological response did not necessarily reflect the repeated exposure. We conclude that despite repeated exposure, neither clinical disease nor serological response can be predicted and that further studies are required to understand the mechanisms behind survival following multiple exposures to lyssaviruses. Crown
Copyright © 2014. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Exposure; Lyssavirus; Mouse; Pathogenicity; Rabies; Virus

Mesh:

Year:  2013        PMID: 24380842     DOI: 10.1016/j.virusres.2013.12.029

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  7 in total

1.  Repeated Low-Dose Influenza Virus Infection Causes Severe Disease in Mice: a Model for Vaccine Evaluation.

Authors:  Yufeng Song; Xiang Wang; Hongbo Zhang; Xinying Tang; Min Li; Jufang Yao; Xia Jin; Hildegund C J Ertl; Dongming Zhou
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

2.  Host Responses to Pathogen Priming in a Natural Songbird Host.

Authors:  Ariel E Leon; Dana M Hawley
Journal:  Ecohealth       Date:  2017-08-01       Impact factor: 3.184

3.  Second case of European bat lyssavirus type 2 detected in a Daubenton's bat in Finland.

Authors:  Tiina Nokireki; Tarja Sironen; Teemu Smura; Veera Karkamo; Liisa Sihvonen; Tuija Gadd
Journal:  Acta Vet Scand       Date:  2017-09-25       Impact factor: 1.695

Review 4.  Lyssaviruses and bats: emergence and zoonotic threat.

Authors:  Ashley C Banyard; Jennifer S Evans; Ting Rong Luo; Anthony R Fooks
Journal:  Viruses       Date:  2014-08-04       Impact factor: 5.048

5.  Efficacy of rabies vaccines in dogs and cats and protection in a mouse model against European bat lyssavirus type 2.

Authors:  Tiina Nokireki; Miia Jakava-Viljanen; Anna-Maija Virtala; Liisa Sihvonen
Journal:  Acta Vet Scand       Date:  2017-10-02       Impact factor: 1.695

6.  Utilisation of Chimeric Lyssaviruses to Assess Vaccine Protection against Highly Divergent Lyssaviruses.

Authors:  Jennifer S Evans; Guanghui Wu; David Selden; Hubert Buczkowski; Leigh Thorne; Anthony R Fooks; Ashley C Banyard
Journal:  Viruses       Date:  2018-03-15       Impact factor: 5.048

7.  Comparative pathogenesis of different phylogroup I bat lyssaviruses in a standardized mouse model.

Authors:  Antonia Klein; Elisa Eggerbauer; Madlin Potratz; Luca M Zaeck; Sten Calvelage; Stefan Finke; Thomas Müller; Conrad M Freuling
Journal:  PLoS Negl Trop Dis       Date:  2022-01-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.